Journal article
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
- Abstract:
-
PURPOSE: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. EXPERIMENTAL DESIGN: This phase II, open-label, multicenter, randomized, parallel-group study examined the effect of 100 mg oral selumetinib twice daily in 28-day cycles versus oral temozolomide (200 mg/m(2)/d for 5 days, then 23 days off-...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Volume:
- 18
- Issue:
- 2
- Pages:
- 555-567
- Publication date:
- 2012-01-01
- DOI:
- EISSN:
-
1557-3265
- ISSN:
-
1078-0432
- Source identifiers:
-
237517
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:237517
- UUID:
-
uuid:ee3b9286-b320-4e02-acd7-c44cb33afa89
- Local pid:
- pubs:237517
- Deposit date:
- 2013-11-16
Terms of use
- Copyright date:
- 2012
If you are the owner of this record, you can report an update to it here: Report update to this record